Second-line and subsequent therapy for ovarian carcinoma.

This publication has 32 references indexed in Scilit:

• Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum
  Acta Oncologica, 2002
• Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
  Journal of Clinical Oncology, 2001
• Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma
  Gynecologic Oncology, 2001
• In vitro induction of tumor-specific human lymphocyte antigen class I–restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen–pulsed autologous dendritic cells from patients with advanced ovarian cancer
  American Journal of Obstetrics and Gynecology, 2000
• Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
  Cancer Gene Therapy, 2000
• Efficacy and Hematologic Toxicity of Salvage Chemotherapy Following Stem Cell-Supported High-Dose Chemotherapy in Women with Recurrent Ovarian Cancer
  Gynecologic Oncology, 2000
• Immunotherapy of Human Ovarian Carcinoma with OVAREX^TMMAb-B43.13 in a Human-PBL-SCID/BG Mouse Model
  Hybridoma, 1999
• Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent
  Gynecologic Oncology, 1998
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
  Journal of Clinical Oncology, 1992
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials
  British Journal of Cancer, 1989